Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 19;13(1):3.
doi: 10.3390/cells13010003.

A Comprehensive Review of the Potential Role of Liquid Biopsy as a Diagnostic, Prognostic, and Predictive Biomarker in Pancreatic Ductal Adenocarcinoma

Kosta Stosic  1 , Oier Azurmendi Senar  1 , Jawad Tarfouss  1 , Christelle Bouchart  1   2 , Julie Navez  1   3 , Jean-Luc Van Laethem  1   4 , Tatjana Arsenijevic  1   4
Affiliations
Review

A Comprehensive Review of the Potential Role of Liquid Biopsy as a Diagnostic, Prognostic, and Predictive Biomarker in Pancreatic Ductal Adenocarcinoma

Kosta Stosic et al. Cells. .

Abstract

Pancreatic ductal adenocarcinoma is one of the most lethal malignant diseases, with a mortality rate being close to incidence. Due to its heterogeneity and plasticity, as well as the lack of distinct symptoms in the early phases, it is very often diagnosed at an advanced stage, resulting in poor prognosis. Traditional tissue biopsies remain the gold standard for making a diagnosis, but have an obvious disadvantage in their inapplicability for frequent sampling. Blood-based biopsies represent a non-invasive method which potentially offers easy and repeated sampling, leading to the early detection and real-time monitoring of the disease and hopefully an accurate prognosis. Given the urgent need for a reliable biomarker that can estimate a patient's condition and response to an assigned treatment, blood-based biopsies are emerging as a potential new tool for improving patients' survival and surveillance. In this article, we discuss the current advances and challenges in using liquid biopsies for pancreatic cancer, focusing on circulating tumour DNA (ctDNA), extracellular vesicles (EVs), and circulating tumour cells (CTCs), and compare the performance and reliability of different biomarkers and combinations of biomarkers.

Keywords: liquid biopsy; pancreatic cancer; tumoural heterogeneity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Cell-free DNA, circulating tumour DNA, and other blood components of an oncology patient.
Figure 2
Figure 2
Circulating tumour cells.
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer Statistics, 2023. CA Cancer J. Clin. 2023;73:17–48. doi: 10.3322/caac.21763. - DOI - PubMed
    1. Ionescu-Tirgoviste C., Gagniuc P.A., Gubceac E., Mardare L., Popescu I., Dima S., Militaru M. A 3D Map of the Islet Routes throughout the Healthy Human Pancreas. Sci. Rep. 2015;5:14634. doi: 10.1038/srep14634. - DOI - PMC - PubMed
    1. Rawla P., Sunkara T., Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J. Oncol. 2019;10:10–27. doi: 10.14740/wjon1166. - DOI - PMC - PubMed
    1. Ducreux M., Cuhna A.S., Caramella C., Hollebecque A., Burtin P., Goéré D., Seufferlein T., Haustermans K., Van Laethem J.L., Conroy T., et al. Cancer of the Pancreas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2015;26:v56–v68. doi: 10.1093/annonc/mdv295. - DOI - PubMed
    1. Macdonald S., Mair F. Tackling Cancers of Unmet Need: The Pancreatic Cancer Pathway. Lancet Gastroenterol. Hepatol. 2016;1:266–267. doi: 10.1016/S2468-1253(16)30113-3. - DOI - PubMed

Publication types